Cytori Therapeutics, Inc is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryBiotechnology
SectorMedical
Phone858-458-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.67 million
Profitability
Miscellaneous
Employees37
Next Earnings DateN/A
OptionableOptionable
Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Cytori Therapeutics's stock reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics Inc (NASDAQ:CYTX) issued its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) EPS for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.02. The biotechnology company had revenue of $0.70 million for the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative return on equity of 272.70%. View Cytori Therapeutics' Earnings History.
What is the consensus analysts' recommendation for Cytori Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytori Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cytori Therapeutics.
What are Wall Street analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. Maxim Group analysts commented, "Cytori reported 4Q18 with product sales of $0.4M (celution system) and contract revenues of $0.7M, net loss was ($2.2M). The company ended the period with $5.3M in cash, which does not include the asset sale announced concurrently with earnings." (4/1/2019)
- 2. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (1/15/2019)
Has Cytori Therapeutics been receiving favorable news coverage?
News stories about CYTX stock have trended somewhat negative on Saturday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cytori Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Cytori Therapeutics.
Who are some of Cytori Therapeutics' key competitors?
Some companies that are related to Cytori Therapeutics include DarioHealth (DRIO), Hancock Jaffe Laboratories (HJLI), Lianluo Smart (LLIT), Obalon Therapeutics (OBLN), Dynatronics (DYNT), Valeritas (VLRX), Avinger (AVGR), Sintx Technologies (SINT), Cytocore (MDIT), CELLECT BIOTECH/S (APOP), Presbia (LENS), Invivo Therapeutics (NVIV), Calmare Therapeutics (CTTC), Encision (ECIA) and Neurometrix (NURO).
What other stocks do shareholders of Cytori Therapeutics own?
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- Marc H. Hedrick, President, Chief Executive Officer & Director
- Gary S. Titus, Chief Financial Officer
- Mark T. Marino, Chief Medical Officer & Senior Vice President
- John K. Fraser, Chief Scientist
- Russ Havranek, VP-Global Marketing & Business Development
How do I buy shares of Cytori Therapeutics?
Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of CYTX stock can currently be purchased for approximately $0.1951.
How big of a company is Cytori Therapeutics?
What is Cytori Therapeutics' official website?
How can I contact Cytori Therapeutics?
Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]
MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
